Montano CB, Patel M, Jain R, Masand PS, Harrington A, Gillard P, Sullivan K, McElroy SL, Brown TM, Nelson L, McIntyre RS. The rapid mood screener: a novel and pragmatic screener tool for bipolar I disorder. CNS Spectr. 2021 Apr;26(2):167-8. doi: 10.1017/S1092852920002709
Davis KL, Kaye JA, Masters ET, Iyer S. Real-world outcomes in patients with ALK-positive non-small cell lung cancer treated with crizotinib. Curr Oncol. 2018 Feb;25(1):e40-9. doi: 10.3747/co.25.3723
Fehnel SE, Forsyth BH, DiBenedetti DB, Danchenko N, Francios C, Brevig T. Patient-centered assessment of cognitive symptoms of depression. CNS Spectr. 2016 Feb;21(1):43-52. doi: 10.1017/S1092852913000643
Farreny A, Aguado J, Ochoa S, Haro JM, Usall J. The role of negative symptoms in the context of cognitive remediation for schizophrenia. Schizophr Res. 2013 Oct;150(1):58-63.
Farreny A, Aguado J, Ochoa S, Huerta-Ramos E, Marsà F, López-Carrilero R, Carral V, Haro JM, Usall J. REPYFLEC cognitive remediation group training in schizophrenia: looking for an integrative approach. Schizophr Res. 2012 Dec;142(1-3):137-44. doi: 10.1016/j.schres.2012.08.035.
Mangel AW, Wang J, Sherrill B, Gnanasakthy A, Ervin C, Fehnel SE. Urgency as an endpoint in irritable bowel syndrome. Gastroenterology Research. 2011 Feb 1;4(1):9-12.
Graham CN, Mauskopf J, Lawson AH, Ascher-Svanum H, Bruhn D, Watson PR. Validating an industry-sponsored model comparing the cost-effectiveness of atypical antipsychotics in the treatment of schizophrenia. Schizophr Res. 2010 Apr 1;117(2-3):398-9.